AVROBIO to Explore Strategic Alternatives

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company, has announced its intention to explore strategic alternatives in order to maximize shareholder value. After conducting a thorough review of its business, the company has decided to temporarily pause the development of its programs and focus on this exploration process. During this evaluation period, AVROBIO will conside..